MA52702A - Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate - Google Patents
Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamateInfo
- Publication number
- MA52702A MA52702A MA052702A MA52702A MA52702A MA 52702 A MA52702 A MA 52702A MA 052702 A MA052702 A MA 052702A MA 52702 A MA52702 A MA 52702A MA 52702 A MA52702 A MA 52702A
- Authority
- MA
- Morocco
- Prior art keywords
- glutamate receptor
- metabotropic glutamate
- allosteric modulator
- chromone oxime
- new chromone
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 229940125516 allosteric modulator Drugs 0.000 title 1
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical compound C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182468 | 2014-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52702A true MA52702A (fr) | 2021-03-31 |
Family
ID=51421865
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052702A MA52702A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA040530A MA40530A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA048048A MA48048A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040530A MA40530A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA048048A MA48048A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10017521B2 (enExample) |
| EP (3) | EP3186257B1 (enExample) |
| JP (1) | JP6430015B2 (enExample) |
| KR (1) | KR101870589B1 (enExample) |
| CN (2) | CN110343118A (enExample) |
| AU (1) | AU2015308438B2 (enExample) |
| CA (1) | CA2956191C (enExample) |
| CY (1) | CY1121352T1 (enExample) |
| DK (1) | DK3186257T3 (enExample) |
| ES (1) | ES2714073T3 (enExample) |
| HR (1) | HRP20190343T1 (enExample) |
| HU (1) | HUE041941T2 (enExample) |
| IL (1) | IL250287B (enExample) |
| LT (1) | LT3186257T (enExample) |
| MA (3) | MA52702A (enExample) |
| ME (1) | ME03339B (enExample) |
| MX (1) | MX369643B (enExample) |
| NZ (1) | NZ728853A (enExample) |
| PL (1) | PL3186257T3 (enExample) |
| PT (1) | PT3186257T (enExample) |
| RS (1) | RS58592B1 (enExample) |
| RU (1) | RU2672569C2 (enExample) |
| SI (1) | SI3186257T1 (enExample) |
| SM (1) | SMT201900152T1 (enExample) |
| TR (1) | TR201903332T4 (enExample) |
| WO (1) | WO2016030444A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52702A (fr) * | 2014-08-27 | 2021-03-31 | Prexton Therapeutics Sa | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| ES2764490T3 (es) * | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
| AU2019309448B2 (en) | 2018-07-26 | 2024-08-29 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| JP3993651B2 (ja) * | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| CA2696016A1 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2011051478A1 (en) | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| WO2011069063A2 (en) | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals, Inc. | Multicyclic compounds and methods of use thereof |
| WO2013107862A1 (en) * | 2012-01-18 | 2013-07-25 | Addex Pharma S.A. | NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| MA52702A (fr) * | 2014-08-27 | 2021-03-31 | Prexton Therapeutics Sa | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| ES2764490T3 (es) | 2015-08-27 | 2020-06-03 | Prexton Therapeutics Sa | Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa |
-
2015
- 2015-08-27 MA MA052702A patent/MA52702A/fr unknown
- 2015-08-27 MA MA040530A patent/MA40530A/fr unknown
- 2015-08-27 CA CA2956191A patent/CA2956191C/en not_active Expired - Fee Related
- 2015-08-27 LT LTEP15770814.0T patent/LT3186257T/lt unknown
- 2015-08-27 SM SM20190152T patent/SMT201900152T1/it unknown
- 2015-08-27 HR HRP20190343TT patent/HRP20190343T1/hr unknown
- 2015-08-27 SI SI201530640T patent/SI3186257T1/sl unknown
- 2015-08-27 EP EP15770814.0A patent/EP3186257B1/en active Active
- 2015-08-27 MX MX2017002429A patent/MX369643B/es active IP Right Grant
- 2015-08-27 AU AU2015308438A patent/AU2015308438B2/en not_active Ceased
- 2015-08-27 CN CN201910567865.9A patent/CN110343118A/zh active Pending
- 2015-08-27 ES ES15770814T patent/ES2714073T3/es active Active
- 2015-08-27 PT PT15770814T patent/PT3186257T/pt unknown
- 2015-08-27 ME MEP-2019-59A patent/ME03339B/me unknown
- 2015-08-27 EP EP19151429.8A patent/EP3502115A1/en not_active Withdrawn
- 2015-08-27 PL PL15770814T patent/PL3186257T3/pl unknown
- 2015-08-27 CN CN201580045432.7A patent/CN106715444B/zh not_active Expired - Fee Related
- 2015-08-27 MA MA048048A patent/MA48048A/fr unknown
- 2015-08-27 DK DK15770814.0T patent/DK3186257T3/en active
- 2015-08-27 EP EP19217991.9A patent/EP3696183A1/en not_active Withdrawn
- 2015-08-27 WO PCT/EP2015/069601 patent/WO2016030444A1/en not_active Ceased
- 2015-08-27 US US15/506,941 patent/US10017521B2/en not_active Expired - Fee Related
- 2015-08-27 KR KR1020177005768A patent/KR101870589B1/ko not_active Expired - Fee Related
- 2015-08-27 TR TR2019/03332T patent/TR201903332T4/tr unknown
- 2015-08-27 RS RS20190289A patent/RS58592B1/sr unknown
- 2015-08-27 JP JP2017530425A patent/JP6430015B2/ja not_active Expired - Fee Related
- 2015-08-27 HU HUE15770814A patent/HUE041941T2/hu unknown
- 2015-08-27 RU RU2017109818A patent/RU2672569C2/ru active
- 2015-08-27 NZ NZ728853A patent/NZ728853A/en not_active IP Right Cessation
-
2017
- 2017-01-25 IL IL250287A patent/IL250287B/en active IP Right Grant
-
2018
- 2018-06-05 US US16/000,338 patent/US10442818B2/en active Active
-
2019
- 2019-03-08 CY CY20191100277T patent/CY1121352T1/el unknown
- 2019-09-30 US US16/587,670 patent/US20200024285A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE057254T2 (hu) | Vegyületek és készítmények az endoszomális Toll-szerû receptorok inhibitoraiként | |
| PT3160964T (pt) | Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos | |
| LT3322701T (lt) | Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai | |
| MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
| EP3200806A4 (en) | Nanofiber structures and methods of synthesis and use thereof | |
| HUE045161T2 (hu) | Hozzáadott emulgeálószerektõl, pufferektõl és stabilizáló sóktól mentes krémpor | |
| HRP20190147T1 (hr) | Benzoksazinon amidi kao modulatori mineralokortikodnih receptora | |
| DK3137873T3 (da) | Viscometer and methods of use thereof | |
| DK3707143T3 (da) | Nye analoger som androgenreceptor- og glucorticoidreceptor-modulatorer | |
| EP3367998A4 (en) | NOVEL METHOD OF USE AND COMPOSITIONS | |
| IL248792A0 (en) | Hsp70 modulators and methods for making and using the same | |
| EP3368401A4 (en) | ANCHOR ADAPTER | |
| EP3191117A4 (en) | Stimulation of ovarian follicle development and oocyte maturation | |
| PL2989875T3 (pl) | Mechanizm dźwigni narzędzia rolniczego | |
| EP3171941A4 (en) | N-methyl-d-aspartate receptor modulators and methods of making and using same | |
| MA48048A (fr) | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate | |
| EP3294748A4 (en) | NOVEL METHYLATION CENTER FOR REGULATING THE EXPRESSION OF MDA-9 / SYNTENIN | |
| IL251230A0 (en) | Converted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors | |
| PL3431106T3 (pl) | Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie | |
| BR112017007799A2 (pt) | dispositivo intrauterino com um movimento restrito de um nó da corda | |
| HUE050459T2 (hu) | Androgénreceptor-gátló kristályformája és annak elõállítási eljárása | |
| EP3659592A4 (en) | NOVEL BENZYLIDENE ACETONE DERIVATIVE AND USE OF IT | |
| HUE053734T2 (hu) | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk | |
| EP3463342A4 (en) | COMBINATIONS OF ESTROGEN RECEPTOR MODULATORS | |
| EP3161483A4 (en) | Point of care immunization testing system - detection methods |